US FDA Advisory Committee Reboot (Part II): The Right Balance For Conflicts Of Interest
Executive Summary
After back-and-forth tinkering with CoI restrictions, CDER is still finding it challenging to seat the right experts. Maybe more realistic guidelines are needed.
You may also be interested in...
US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time
FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.
US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time
FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.
US FDA Advisory Committee Reboot (Part III): Asking The Right Questions
Rethinking the voting and discussion questions to advisory committees may be one way to ensure FDA gets the advice it needs.